Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2008 Apr 16;2008(2):CD006792.
doi: 10.1002/14651858.CD006792.pub2.

Traditional corticosteroids for induction of remission in Crohn's disease

E I Benchimol  1 , C H Seow, A H Steinhart, A M Griffiths
Affiliations
Meta-Analysis

Traditional corticosteroids for induction of remission in Crohn's disease

E I Benchimol et al. Cochrane Database Syst Rev. .

Abstract

Background: Historically, corticosteroids have been the most commonly used class of medication for induction of remission in Crohn's disease (CD). Corticosteroids down regulate production of inflammatory cytokines and interfere with NF-kappaB production, thereby blunting inflammatory response.

Objectives: The primary objective was to systematically review the efficacy and safety of traditional corticosteroids (given orally or intravenously) for induction of remission in CD.

Search strategy: The following electronic databases were searched: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders (IBD/FBD) Group Specialized Trial Register, and ClinicalTrials.gov. No language restrictions were applied. Reference lists of trials and review articles, as well as recent proceedings from major gastroenterology meetings were manually searched.

Selection criteria: Randomized, controlled clinical trials of traditional, systemic corticosteroids for the induction of remission of active CD were included in this review. Control groups included patients receiving either placebo or 5-aminosalicylates (5-ASA). The study population included patients of any age with active CD (as defined by the study authors or validated clinical activity indices), receiving any formulation of systemically available corticosteroid by any oral or parenteral methods of delivery. The primary outcome was induction of remission of CD. Secondary outcomes included clinical response, change in mean CDAI, adverse events and the proportion of patients withdrawing due to adverse events.

Data collection and analysis: Two independent investigators reviewed studies for eligibility, extracted the data and assessed study quality using Jadad's criteria. A random or fixed effects model was chosen based on an assessment of heterogeneity, and studies were weighted using the DerSimonian & Laird or the Mantel-Haenszel method accordingly. Meta-analysis was performed using RevMan 4.2.10 software.

Main results: Two studies compared corticosteroids to placebo and six studies compared corticosteroids to 5-ASA. Corticosteroids were found to be significantly more effective than placebo at inducing remission in CD (RR 1.99; 95% CI 1.51 to 2.64; P < 0.00001). Corticosteroids were found to be more effective than 5-ASA at inducing remission in studies with long follow-up duration (i.e. > 15 weeks; RR 1.65; 95% CI 1.33 to 2.03; P < 0.00001). Corticosteroids induced adverse events in a higher proportion of patients than placebo (RR 4.89; 95% CI 1.98 to 12.07; P = 0.0006), or low-dose 5-ASA (RR 2.38; 95% CI 1.34 to 4.25; P = 0.003). No difference existed in the proportion of patients experiencing adverse events when steroids were compared to high-dose 5-ASA. Steroids did not induce more study withdrawals due to adverse events than either placebo or 5-ASA.

Authors' conclusions: Corticosteroids are effective for induction of remission in patients with CD, particularly when used for more than 15 weeks. Although corticosteroids cause more adverse events than either placebo or low-dose 5-ASA, these adverse events did not lead to increased study withdrawal in the included studies. Further information is required to determine the optimal duration of treatment and tapering protocol to maximize the efficacy of treatment with corticosteroids. Additionally, further study is required to determine whether corticosteroids are more effective in patients with certain phenotypes or when administered intravenously.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

Analysis 1.1
Analysis 1.1
Comparison 1 Corticosteroids vs. placebo, Outcome 1 Remission rate (Late, 15+ weeks).
Analysis 1.2
Analysis 1.2
Comparison 1 Corticosteroids vs. placebo, Outcome 2 Development of Any Adverse Event.
Analysis 1.3
Analysis 1.3
Comparison 1 Corticosteroids vs. placebo, Outcome 3 Withdrawal From Study Due To Adverse Event.
Analysis 1.4
Analysis 1.4
Comparison 1 Corticosteroids vs. placebo, Outcome 4 Response to Treatment.
Analysis 2.1
Analysis 2.1
Comparison 2 Corticosteroids vs. 5‐ASA, Outcome 1 Remission Rate (Late, 15+ weeks) (Max Pred 60 mg/day + 5‐ASA 1.2‐2 g/day).
Analysis 2.2
Analysis 2.2
Comparison 2 Corticosteroids vs. 5‐ASA, Outcome 2 Remission Rate (Late, 15+ weeks) (Sensitivity Analysis ‐ Sulfasalazine studies only).
Analysis 2.3
Analysis 2.3
Comparison 2 Corticosteroids vs. 5‐ASA, Outcome 3 Development of Any Adverse Event.
Analysis 2.4
Analysis 2.4
Comparison 2 Corticosteroids vs. 5‐ASA, Outcome 4 Development of Any Adverse Event (Sensitivity Analysis ‐ Removed high‐dose 5‐ASA studies).
Analysis 2.5
Analysis 2.5
Comparison 2 Corticosteroids vs. 5‐ASA, Outcome 5 Withdrawal from Study Due to Adverse Event.
Analysis 2.6
Analysis 2.6
Comparison 2 Corticosteroids vs. 5‐ASA, Outcome 6 Response to Treatment.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD006792

References

References to studies included in this review

    1. Gross V, Andus T, Fischbach W, Weber A, Gierend M, Hartmann F, et al. Comparison between high dose 5‐aminosalicylic acid and 6‐methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double‐blind study. German 5‐ASA Study Group. Z Gastroenterol 1995;33(10):581‐4. - PubMed
    1. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86(2):249‐66. - PubMed
    1. Martin F, Sutherland L, Beck IT, Anderson AH, Williams CN, Saibil F, et al. Oral 5‐ASA versus prednisone in short term treatment of Crohn's disease: A multicentre controlled trial. Can J Gastroenterol 1990;4(7):452‐7.
    1. Prantera C, Cottone M, Pallone F, Annese V, Franze A, Cerutti R, et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology 1999;116(3):521‐6. - PubMed
    1. Scholmerich J, Jenss H, Hartmann F, Dopfer H. Oral 5‐aminosalicylic acid versus 6‐methylprednisolone in active Crohn's disease. Can J Gastroenterol 1990;4(7):446‐51.

References to studies excluded from this review

    1. Bergman L, Krause U. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease. Scand J Gastroenterol 1976;11(7):651‐6. - PubMed
    1. Brignola C, Simone G, Belloli C, Iannone P, Belluzzi A, Gionchetti P, et al. Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther 1994;8(4):465‐8. - PubMed
    1. Chun A, Chadi RM, Korelitz BI, Colonna T, Felder JB, Jackson MH, et al. Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double‐blind study and follow‐up. Inflamm Bowel Dis 1998;4(3):177‐81. - PubMed
    1. Gaia E, Morello C, Roatta L, Cavallero M, Bonard R, Banche M. [Use of a chronomulticorticoid in the treatment of Crohn's disease]. Clin Ter 1979;90(4):325‐33. - PubMed
    1. Jenss H, Hartmann F, Scholmerich J. 5‐aminosalicylic acide versus methylprednisolone in the treatment of active Crohn disease. Gastroenterology 1989;96(5 Part 2):A239.

Additional references

    1. Akobeng AK, Zachos M. Tumor necrosis factor‐alpha antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2004, Issue 1. - PMC - PubMed
    1. Akobeng AK, Gardener E. Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's Disease. Cochrane Database of Systematic Reviews 2005, Issue 1. - PubMed
    1. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database of Systematic Reviews 2005, Issue 1. - PubMed
    1. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2(8044):892‐5. - PubMed
    1. Barnes PJ, Adcock I. Anti‐inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993;14(12):436‐41. - PubMed

MeSH terms

Substances